Skip to main content

Advertisement

SpringerLink
Log in

Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer

  • Preclinical Study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors which have been implicated in breast cancer. The aim of this study was to evaluate FGFR-1, -2, -3, and -4 protein expressions in normal murine mammary gland development, and in murine and human breast carcinomas. Using immunohistochemistry and Western blot, we report a hormonal regulation of FGFR during postnatal mammary gland development. Progestin treatment of adult virgin mammary glands resulted in changes in localization of FGFR-3 from the cytoplasm to the nucleus, while treatment with 17-β-estradiol induced changes in the expressions and/or localizations of FGFR-2 and -3. In murine mammary carcinomas showing different degrees of hormone dependence, we found progestin-induced increased expressions, mainly of FGFR-2 and -3. These receptors were constitutively activated in hormone-independent variants. We studied three luminal human breast cancer cell lines growing as xenografts, which particularly expressed FGFR-2 and -3, suggesting a correlation between hormonal status and FGFR expression. Most importantly, in breast cancer samples from 58 patients, we found a strong association (P < 0.01; Spearman correlation) between FGFR-2 and -3 expressions and a weaker correlation of each receptor with estrogen receptor expression. FGFR-4 correlated with c-erbB2 over expression. We conclude that FGFR-2 and -3 may be mechanistically linked and can be potential targets for treatment of estrogen receptor-positive breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Morrison RS, Yamaguchi F, Bruner JM et al (1994) Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res 54:2794–2799

    PubMed  CAS  Google Scholar 

  2. Yoshimura N, Sano H, Hashiramoto A et al (1998) The expression and localization of fibroblast growth factor-1 (FGF-1) and FGF receptor-1 (FGFR-1) in human breast cancer. Clin Immunol Immunopathol 89:28–34

    Article  PubMed  CAS  Google Scholar 

  3. Giri D, Ropiquet F, Ittmann M (1999) Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5:1063–1071

    PubMed  CAS  Google Scholar 

  4. Ahmed NU, Ueda M, Ito AM et al (1997) Expression of fibroblast growth factor receptors in naevus-cell naevus and malignant melanoma. Melanoma Res 7:299–305

    Article  PubMed  CAS  Google Scholar 

  5. Myoken Y, Myoken Y, Okamoto T et al (1996) Expression of fibroblast growth factor-1 (FGF-1), FGF-2 and FGF receptor-1 in a human salivary-gland adenocarcinoma cell line: evidence of growth. Int J Cancer 65:650–657

    Article  PubMed  CAS  Google Scholar 

  6. Shingu K, Fujimori M, Ito K et al (1998) Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 in thyroid diseases: difference between neoplasms and hyperplastic lesions. Endocr J 45:35–43

    Article  PubMed  CAS  Google Scholar 

  7. Bernard RS, Zheng L, Liu W et al (2005) Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 146:1145–1153

    Article  Google Scholar 

  8. Powers CJ, McLeskey SW, Wellstein A (2000) Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7:165–197

    Article  PubMed  CAS  Google Scholar 

  9. Hynes NE, Dey JH (2010) Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Res 70:5199–5202

    Article  PubMed  CAS  Google Scholar 

  10. Giulianelli S, Cerliani JP, Lamb CA et al (2008) Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis. Int J Cancer 123:2518–2531

    Article  PubMed  CAS  Google Scholar 

  11. Cerliani JP, Guillardoy T, Giulianelli S et al (2011) Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. Cancer Res 71:3720–3731

    Article  PubMed  CAS  Google Scholar 

  12. Imagawa W, Pedchenko VK, Helber J et al (2000) Attenuation and loss of hormonal modulation of KGF (FGF-7)/KGF receptor expression and mitogenesis during mammary tumor progression. J Cell Physiol 184:222–228

    Article  PubMed  CAS  Google Scholar 

  13. Ishii K, Imamura T, Iguchi K et al (2009) Evidence that androgen-independent stromal growth factor signals promote androgen-insensitive prostate cancer cell growth in vivo. Endocr Relat Cancer 16:415–428

    Article  PubMed  CAS  Google Scholar 

  14. Chodosh LA, Gardner HP, Rajan JV et al (2000) Protein kinase expression during murine mammary development. Dev Biol 219:259–276

    Article  PubMed  CAS  Google Scholar 

  15. Shiang CY, Qi Y, Wang B et al (2010) Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res Treat 123:747–755

    Article  PubMed  CAS  Google Scholar 

  16. Turner N, Pearson A, Sharpe R et al (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70:2085–2094

    Article  PubMed  CAS  Google Scholar 

  17. Institute of Laboratory Animal Resources CoLSNRC (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington, DC

    Google Scholar 

  18. Lanari C, Lamb CA, Fabris VT et al (2009) The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 16:333–350

    Article  PubMed  CAS  Google Scholar 

  19. Bloom HJG, Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11:359–377

    Article  PubMed  CAS  Google Scholar 

  20. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410

    Article  PubMed  CAS  Google Scholar 

  21. Vanzulli SI, Soldati R, Meiss R et al (2005) Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression. Carcinogenesis 26:1055–1063

    Article  PubMed  CAS  Google Scholar 

  22. Molinolo AA, Hewitt SM, Amornphimoltham P et al (2007) Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13:4964–4973

    Article  PubMed  CAS  Google Scholar 

  23. Helguero LA, Viegas M, Asaithamby A et al (2003) Progesterone receptor expression in medroxyprogesterone acetate-induced murine mammary carcinomas and response to endocrine treatment. Breast Cancer Res Treat 79:379–390

    Article  PubMed  CAS  Google Scholar 

  24. Brisken C, O’Malley B (2010) Hormone action in the mammary gland. Cold Spring Harb Perspect Biol 2:a003178

    Article  PubMed  CAS  Google Scholar 

  25. Montero GG, Vanzulli SI, Cerliani JP et al (2007) Association of estrogen receptor alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. Breast Cancer Res 9:R22

    Article  Google Scholar 

  26. Pandit SG, Govindraj P, Sasse J et al (2002) The fibroblast growth factor receptor, FGFR3, forms gradients of intact and degraded protein across the growth plate of developing bovine ribs. Biochem J 361:231–241

    Article  PubMed  CAS  Google Scholar 

  27. Zhu X, Asa SL, Ezzat S (2009) Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. Mol Endocrinol 23:1397–1405

    Article  PubMed  CAS  Google Scholar 

  28. Hollestelle A, Nagel JH, Smid M et al (2010) Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat 121:53–64

    Article  PubMed  Google Scholar 

  29. Bruzzone A, Vanzulli SI, Soldati R et al (2009) Novel human breast cancer cell lines IBH-4, IBH-6, and IBH-7 growing in nude mice. J Cell Physiol 219:477–484

    Article  PubMed  CAS  Google Scholar 

  30. Lu P, Ewald AJ, Martin GR et al (2008) Genetic mosaic analysis reveals FGF receptor 2 function in terminal end buds during mammary gland branching morphogenesis. Dev Biol 321:77–87

    Article  PubMed  CAS  Google Scholar 

  31. Parsa S, Ramasamy SK, De Langhe S et al (2008) Terminal end bud maintenance in mammary gland is dependent upon FGFR2b signaling. Dev Biol 317:121–131

    Article  PubMed  CAS  Google Scholar 

  32. Pond AC, Herschkowitz JI, Schwertfeger KL et al (2010) Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res 70:4868–4879

    Article  PubMed  CAS  Google Scholar 

  33. Johnston CL, Cox HC, Gomm JJ et al (1995) Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus. J Biol Chem 270:30643–30650

    Article  PubMed  CAS  Google Scholar 

  34. Tannheimer SL, Rehemtulla A, Ethier SP (2000) Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2:311–320

    Article  PubMed  CAS  Google Scholar 

  35. Luqmani YA, Graham M, Coombes RC (1992) Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 66:273–280

    Article  PubMed  CAS  Google Scholar 

  36. Turner N, Lambros MB, Horlings HM et al (2010) Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29:2013–2023

    Article  PubMed  CAS  Google Scholar 

  37. Fillmore CM, Gupta PB, Rudnick JA et al (2010) Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci USA 107:21737–21742

    Article  PubMed  CAS  Google Scholar 

  38. Thussbas C, Nahrig J, Streit S et al (2006) FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 24:3747–3755

    Article  PubMed  CAS  Google Scholar 

  39. Bange J, Prechtl D, Cheburkin Y et al (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62:840–847

    PubMed  CAS  Google Scholar 

  40. Sharpe R, Pearson A, Herrera-Abreu MT et al (2011) FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 17:5275–5286

    Article  PubMed  CAS  Google Scholar 

  41. Gelsi-Boyer V, Orsetti B, Cervera N et al (2005) Comprehensive profiling of 8p11–12 amplification in breast cancer. Mol Cancer Res 3:655–667

    Article  PubMed  CAS  Google Scholar 

  42. Gowardhan B, Douglas DA, Mathers ME et al (2005) Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 92:320–327

    PubMed  CAS  Google Scholar 

  43. Martin AJ, Grant A, Ashfield AM et al (2011) FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype. BMC Res Notes 4:72

    Article  PubMed  CAS  Google Scholar 

  44. Zammit C, Barnard R, Gomm JC et al (2001) Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer. J Pathol 194:27–34

    Article  PubMed  CAS  Google Scholar 

  45. Kuroso K, Imai Y, Kobayashi M et al (2010) Immunohistochemical detection of fibroblast growth factor receptor 3 in human breast cancer: correlation with clinicopathological/molecular parameters and prognosis. Pathobiology 77:231–240

    Article  PubMed  CAS  Google Scholar 

  46. Zhu X, Asa SL, Ezzat S (2010) Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer. Am J Pathol 176:2333–2343

    Article  PubMed  CAS  Google Scholar 

  47. Easton DF, Pooley KA, Dunning AM et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087–1093

    Article  PubMed  CAS  Google Scholar 

  48. Marian C, Ochs-Balcom HM, Nie J et al (2010) FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors. Int J Cancer 129:702–712

    Article  PubMed  Google Scholar 

  49. Garcia-Closas M, Chanock S (2008) Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 14:8000–8009

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Julieta Bolado, Bruno Luna, and Pablo DoCampo for their excellent technical assistance. The authors are also grateful to Dr. Ciriano, Roche Argentina, and Dr. Acosta for evaluating Her2; and to Dr Luthy for providing the IBH-6 cell line. MCB received an ICRETT Fellowship from the UICC permitting training in Dr Gutkind’s laboratory at NIH. This study was supported by Sales Foundation, SECyT (PICT 08, No. 989), and CONICET (PIP 2010-2012 N°692). Dr. Hewitt and Dr Molinolo are supported by the Intramural Research Program of the NCI, and the NIDCR from the National Institutes of Health, respectively. JPC, CPP, MCB, AS, and CAL carried out experiments. SIV and AAM analyzed breast cancer samples. MN carried out the statistical analysis of human samples. RV, RM, and EZ provided the cancer samples. SMH prepared the mouse tissue array. CL and CAL conceived the experiments and wrote the paper. All the authors gave final approval to the submitted version.

Conflict of interest

The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Institute of Experimental Biology and Medicine (IBYME), CONICET, Vuelta de Obligado 2490, C1428ADN, Buenos Aires, Argentina

    Juan P. Cerliani, Cecilia Pérez Piñero, María C. Bottino, Ana Sahores, Claudia Lanari & Caroline A. Lamb

  2. NIDCR, NIH, Bethesda, MD, USA

    Alfredo A. Molinolo

  3. National Academy of Medicine, Buenos Aires, Argentina

    Silvia I. Vanzulli

  4. Policlínica Bancaria, Buenos Aires, Argentina

    Romina Varchetta, Rubén Martins & Eduardo Zeitlin

  5. Mathematics Department, University of Buenos Aires, Buenos Aires, Argentina

    Myriam Nuñez

  6. National Cancer Institute, NIH, Bethesda, MD, USA

    Stephen M. Hewitt

Authors
  1. Juan P. Cerliani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silvia I. Vanzulli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cecilia Pérez Piñero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. María C. Bottino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ana Sahores
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Myriam Nuñez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Romina Varchetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rubén Martins
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Eduardo Zeitlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Stephen M. Hewitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Alfredo A. Molinolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Claudia Lanari
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Caroline A. Lamb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caroline A. Lamb.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cerliani, J.P., Vanzulli, S.I., Piñero, C.P. et al. Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer. Breast Cancer Res Treat 133, 997–1008 (2012). https://doi.org/10.1007/s10549-011-1883-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-011-1883-6

Keywords

Search

Navigation